The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl Z is -O-, -NH- or -S- n is 0-5 m is 0-3 R1 and R2 are defined herein including groups: (i) Q1X1 wherein Q1 and X1 are as defined herein (ii) Q15W3 wherein Q15 and W3 are as defined herein, (iii) Q21W4C1-5alkylX1- wherein Q21, W4 and X1 are as defined herein, (iv) Q28C1-5alkylX1-, Q28C2-5alkenylX1- or Q28C2-5alkynylX1- wherein Q28 and X1 are as defined herein and (v) Q29C1-5alkylX1-, Q29C2-5alkenylX1- or Q29C2-5alkynylX1- wherein Q29 and X1 are as defined herein R2 can also be 6,7-methylenedioxy or 6,7-ethylenedioxyand salts thereof their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm?blooded animals processes for the preparation of such compounds intermediates used in such processes processes for making such intermediates pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of formula I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.Linvention porte: sur des composés de formule (I) dans laquelle: le cycle C défini dans la description est par exemple de lindolyle, de lindazolyle ou de lazaindolyle Z est -O-, -NH- ou -S- n est 0-5 m est 0-3 R1 et R2 sont tels que définis dans la description et comportent les groupes: (i) Q1X1, où Q1 et X1 sont tels que définis dans la description (ii) Q15 W3, où Q15 et W3 sont tels que définis dans la description (iii) Q21 W4C1-5 alkyle X1-, où Q21 et W4 sont tels que définis dans la description (iv) Q28 C1-5 alkyleX1-, Q28 C2-5 alcényle X1- ou Q 28 C2-5 alkynyle X1-, où Q28 et X1 sont tels que définis da
